(Q36065420)

12 August 2017

1 reference

title

Discovery, clinical development, and therapeutic uses of bisphosphonates (English)

1 reference

12 August 2017

Angelo A Licata

1

1 reference

PubMed ID

15755793

12 August 2017

language of work or name

English

0 references

publication date

8 March 2005

1 reference

Annals of Pharmacotherapy

12 August 2017

1 reference

12 August 2017

39

1 reference

12 August 2017

4

1 reference

12 August 2017

668-677

1 reference

Guidelines on the management of Paget's disease of bone

12 August 2017

1 reference

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

A review of the physiological and pharmacological effects of pyrophosphate and diphosphonates on bones and teeth

21 January 2018

1 reference

Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging

21 January 2018

1 reference

The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals

21 January 2018

1 reference

The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo.

21 January 2018

1 reference

Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats

21 January 2018

1 reference

Diphosphonates in the treatment of myositis ossificans.

21 January 2018

1 reference

Bisphosphonates: pharmacology, mechanisms of action and clinical uses

21 January 2018

1 reference

Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships

21 January 2018

1 reference

Bisphosphonates: mechanisms of action

21 January 2018

1 reference

Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.

21 January 2018

1 reference

The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis

21 January 2018

1 reference

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

Studies of the oral bioavailability of alendronate.

21 January 2018

1 reference

Bisphosphonates: a review of their pharmacokinetic properties

21 January 2018

1 reference

Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration

21 January 2018

1 reference

The absolute bioavailability of clodronate from two different oral doses

21 January 2018

1 reference

Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis

21 January 2018

1 reference

The effect of dosing regimen on the pharmacokinetics of risedronate

21 January 2018

1 reference

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

21 January 2018

1 reference

New bisphosphonates in the treatment of bone diseases

21 January 2018

1 reference

Effect of renal function on risedronate pharmacokinetics after a single oral dose

21 January 2018

1 reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

21 January 2018

1 reference

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

21 January 2018

1 reference

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

21 January 2018

1 reference

A method to assess the proportion of treatment effect explained by a surrogate endpoint

21 January 2018

1 reference

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone

21 January 2018

1 reference

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment

21 January 2018

1 reference

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

Oral weekly ibandronate prevents bone loss in postmenopausal women

21 January 2018

1 reference

Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

21 January 2018

1 reference

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

21 January 2018

1 reference

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

21 January 2018

1 reference

Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate

21 January 2018

1 reference

Intravenously administered pamidronate in the treatment of Paget's disease of bone

21 January 2018

1 reference

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

Efficacy of risedronate on clinical vertebral fractures within six months.

21 January 2018

1 reference

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

21 January 2018

1 reference

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

21 January 2018

1 reference

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

21 January 2018

1 reference

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis

21 January 2018

1 reference

Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate

21 January 2018

1 reference

A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone

21 January 2018

1 reference

Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.

21 January 2018

1 reference

Intermittent cyclic tiludronate in the treatment of osteoporosis

21 January 2018

1 reference

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

21 January 2018

1 reference

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

Compliance with pharmacologic therapy for osteoporosis

21 January 2018

1 reference

Clinical use of bone densitometry: scientific review

21 January 2018

1 reference

Bone strength and its determinants

21 January 2018

1 reference

Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography

21 January 2018

1 reference

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

21 January 2018

1 reference

Tiludronate therapy for Paget's disease of bone

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E357

1 reference

12 August 2017

1 reference

PubMed ID

15755793